

## Special Issue

# The Role of Immunotherapy in Squamous Cell Carcinoma

### Message from the Guest Editor

In the realm of immunotherapy combinations, novel approaches are being tested such as program cell death 1 inhibitors and vaccines for HPV+ tumors, novel check point inhibitor combinations, cellular therapies, metronomic chemotherapy among others. Last but not least, a topic of interest is the use of novel therapies after progression on immune check point inhibitors.

This Special Issue will highlight the current state of the art in squamous cell carcinomas treatment with immunotherapy and potential therapies available for treatment after progression on immunotherapy. This issue will also highlight the role of predictive markers for better selection of patients that will benefit from an initial treatment with immunotherapy. Lastly, this issue will highlight the emerging role of novel immunotherapy targets and newer combination therapies for the management of this patient population.

---

### Guest Editor

Dr. Markus Heppt

Department of Dermatology, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), 91054 Erlangen, Germany

---

### Deadline for manuscript submissions

closed (30 April 2023)



## Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/si/104540](https://mdpi.com/si/104540)

*Cancers*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[cancers@mdpi.com](mailto:cancers@mdpi.com)

[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)





# Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)



## About the Journal

### Message from the Editor-in-Chief

*Cancers* (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

---

### Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)